Mergers and Acquisitions 17 December 2025 - 31 December 2025

Amicus Therapeutics, Inc. is trading like a classic “deal stock” on December 22, 2025—hovering just below a fixed cash acquisition price after BioMarin Pharmaceutical agreed to buy the company in an all-cash transaction. As of the latest available trade on Dec. 22, FOLD is around $14.22, with the market effectively pricing in the probability, timing, and risk of the merger closing—rather than the stand-alone upside of Amicus’ rare disease commercial portfolio.

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. has effectively become a “deal stock” — the market is now trading the shares primarily on the odds and timing of a takeover rather than on classic biotech catalysts. The reason is simple: on December 19, 2025, BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus for $14.50 per share in cash, valuing Amicus at about $4.8 billion. SEC+1

Amicus Therapeutics, Inc. has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at about $4.8 billion. The offer price—$14.50 per share in cash—instantly reset the “center of gravity” for FOLD shares and shifted investor focus from traditional biotech catalysts to merger timing, regulatory approvals, and closing risk. SEC+1 As of the latest available pricing around Dec. 20, 2025, Amicus shares were trading around $14.18, after a sharp, deal-driven move that pushed the stock close to the $14.50 takeout value. Trading was highly active, with the stock ranging roughly from the low-$11s to the mid-$14s during the session following the announcement—typical behavior for a cash-deal target as the market rapidly reprices to the offer while leaving a small “deal spread.” Reuters